Tactile Systems Technology(NASDAQ) TCMD

Tactile Systems Technology, Inc. treats chronic health conditions at home. Its devices use air-powered compression for swelling and lung issues. These solutions help patients avoid frequent hospital visits for therapy.

Swelling and Airway Treatments

• Lymphedema Products: Air-powered compression devices like Flexitouch Plus and Nimbl used to manage swelling; accounted for 84% of revenue in the six-month period ended June 30, 2026.
• Airway Clearance Products: Portable vests like AffloVest that clear lungs for patients with respiratory conditions; represented 16% of revenue in the six-month period ended June 30, 2026.

Growth Through New Tech

• Acquired LymphaTech in Feb. 2026 to add digital three-dimensional body measurement technology for swelling monitoring.
• Entered a three-year exclusive deal in April 2026 to distribute MyoSleeve devices to government health channels for veterans and military members.
• Launched the Nimbl compression platform for lower-body treatment in Feb. 2025.
• Introduced the AffloVest Gen 6 airway clearance device in June 2026 following regulatory clearance.

What Makes the Model Work

The company manages insurance claims and provides training directly to patients for its swelling treatment devices. It also maintains a specialized clinical team to support doctors and develop medical evidence for its treatments.

Checking the Vitals

• Revenue was $161.0 million in the six-month period ended June 30, 2026, up 15% year over year.
• Net income reached $6.0 million in the six-month period ended June 30, 2026.
• Gross margin was 76% in the six-month period ended June 30, 2026, up 1 percentage point year over year.
• Market cap was $675.3 million in Q2 2026, up 188.4% year over year.

Bottom Line

Tactile Medical has shifted from a single-product firm to a provider of multiple at-home therapies for chronic diseases. The expansion into respiratory care and digital monitoring tools supports its transition into a broader medical technology platform.